(Updated - October 12, 2015 8:30 AM EDT)

Esperion Therapeutics (NASDAQ: ESPR) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Trader Talk

Piper Jaffray Cuts Price Target on Eli Lilly & Co. (LLY) Following Announced Discontinuation of Evacetrapib October 13, 2015 8:38 AM Eli Lilly (LLY) ACCELERATE Trial Proves 'Modestly Positive' for Esperion Therapeutics (ESPR) LDL Hypothesis - StifelOctober 12, 2015 3:07 PM Discontinuation of Evacetrapib Study Could Provide Modest Boost to Esperion's (ESPR) ETC-1002October 12, 2015 1:01 PM Eli Lilly's (LLY) Reaction to Disappointing Evacetrapib Data Appears 'Overdone', Says BofA/MLOctober 12, 2015 11:30 AM Eli Lilly (LLY) Eva Failure Increases Dependence on Sola, BMO Capital NotesOctober 12, 2015 11:12 AM Eli Lilly's (LLY) Hold Rating Maintained at Deutsche Bank (MRK) (AMGN)October 12, 2015 10:14 AM Lilly's (LLY) CETP Inhibitor Disappointment Seen as Positive for Esperion (EPSR) and PCSK-9, Says RBC (REGN) (AMGN) (SNY) (MDCO) (MRK)October 12, 2015 9:13 AM Eli Lilly & Co. (LLY) to Discontinue Development of EvacetrapibOctober 12, 2015 8:01 AM